Sugi Predict

Sugi Predict / Compounds / SCHEMBL224092

SCHEMBL224092

SCHEMBL224092

O=C(NO)c1[c]cccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 8/20 0.46
▸ HDAC6 Q9UBN7 6/20 0.46
▸ HDAC1 Q13547 5/20 0.46
▸ HDAC2 Q92769 3/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ IDO1 P14902 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NCOR2 Q9Y618 1/20 0.46
▸ GAA P10253 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MPO P05164 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ MMP3 P08254 1/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904390 0.81 GAA (0.39) CA1CA9GAAKDM4EMPO
SCHEMBL295086 0.81 GAA (0.42) HDAC8HDAC6HDAC2GAAKDM4E
SCHEMBL483177 0.78 RAB9A (0.49) HDAC8HDAC6HDAC2HSD17B10GAA
SCHEMBL143892 0.77 ALDH1A1 (0.38) ALOX15MEN1KMT2A
SCHEMBL1444015 0.76 ALOX15 (0.41) ALOX15GAAKDM4ESMN1; SMN2MEN1
SCHEMBL1115346 0.76 SMN1; SMN2 (0.41) GAAKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL97054 0.76 KMT2A (0.43) HDAC6HDAC1CA1ALOX15CA9
SCHEMBL1444553 0.76 MYC (0.44) KDM4EKMT2A
SCHEMBL17979561 0.76 RAB9A (0.34) CA12CA9KDM4EMEN1KMT2A
SCHEMBL8993152 0.76 CTSD (0.36) HSD17B10KDM4ESMN1; SMN2KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105748484-A Methods of targeted treatment of frontotemporal lobar degeneration 福拉姆医药股份有限公司 2016-07-13 — — CN claimed
EP-2534132-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2012-12-19 — — EP claimed
EP-2507243-A1 SPIROINDOLINONE PYRROLIDINES F. Hoffmann-La Roche AG (CH) 2012-10-10 — — EP claimed
US-8217044-B2 Spiroindolinone pyrrolidines HOFFMANN-LA ROCHE INC. (US) 2012-07-10 — — US claimed
US-8088815-B2 Spiroindolinone pyrrolidines HOFFMAN-LA ROCHE INC. (US) 2012-01-03 — — US claimed
WO-2011134925-A1 SPIROINDOLINONE PYRROLIDINES F. HOFFMANN-LA ROCHE AG (CH) 2011-11-03 — — WO claimed
US-20110269809-A1 SPIROINDOLINONE PYRROLIDINES HOFFMANN-LA ROCHE INC. 2011-11-03 — — US claimed
WO-2011098398-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-08-18 — — WO claimed
WO-2011067185-A1 SPIROINDOLINONE PYRROLIDINES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-09 — — WO claimed
US-20110130398-A1 SPIROINDOLINONE PYRROLIDINES BARTKOVITZ DAVID JOSEPH 2011-06-02 — — US claimed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 — — EP claimed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 — — WO claimed
CN-107847600-B Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors 豪夫迈·罗氏有限公司 2021-09-03 — — CN disclosed
CN-105378112-B mRNA-based gene expression for personalizing patient cancer therapy with MDM2 antagonists 豪夫迈·罗氏有限公司 2020-10-13 — — CN disclosed
CN-106716131-B Patient personalization methods for cancer therapy with MDM2 antagonists 豪夫迈·罗氏有限公司 2020-07-24 — — CN disclosed
EP-3204776-B1 METHODS FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 — — US disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 — — WO disclosed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 — — US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 HDAC8 652/4885HDAC6 181/4885HDAC1 57/4885
US-20110269809-A1 SPIROINDOLINONE PYRROLIDINES RB1, KRAS, PKD1 HDAC8 216/4885HDAC6 185/4885HDAC1 23/4885
US-20110130398-A1 SPIROINDOLINONE PYRROLIDINES RPS4Y1, RB1, RPS4X HDAC8 344/4885HDAC6 391/4885HDAC1 57/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 HDAC8 652/4885HDAC6 181/4885HDAC1 57/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 HDAC8 218/4885HDAC6 802/4885HDAC1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.